DESTINY-Breast03 Phase 3 Study Results
Conclusions
Daiichi-Sankyo
Preliminary results of BEGONIA show that Dato-DXd + durvalumab demonstrated a robust
response rate in first line a/mTNBC in a biomarker-unselected population
-
-
Confirmed ORR was 74%, with all patients ongoing response at the time of data cut-off
Responses were observed regardless of PD-L1 expression
The combination of Dato-DXd + durvalumab had a manageable safety profile consistent with the
known profile of the individual agents, with no new safety signals
-
No dose-limiting toxicities
- Stomatitis and low-grade nausea and alopecia were the most frequent AEs
-
· Low rates of diarrhea, and no cases of ILD/pneumonitis or neutropenic events, were reported
Enrollment to Part 2 Dato-DXd + durvalumab arm is currently ongoing; follow-up continues in
order to determine duration of response and PFS/OS
ESMO BC 2022 #166 Mini Oral
a/mTNBC, locally advanced/metastatic triple negative breast cancer; Dato-DXd, datopotamab deruxtecan; ORR, objective response rate. 81View entire presentation